Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide in Xeroderma Pigmentosum (XP-C and XP-V)
NCT05370235Phase 2Recruiting
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of Afamelanotide in Xeroderma pigmentosum group C (XPC), Xeroderma pigmentosum variant (XPV), sponsored by Clinuvel Pharmaceuticals. Started Mar 2022; status: recruiting.
02
Drugs
Afamelanotide
03
Conditions
Xeroderma pigmentosum group C (XPC)Xeroderma pigmentosum variant (XPV)
Beyond the preview
Go deeper on NCT05370235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370235.